Investing

Avidity Biosciences : RNA

RNA

Stock Data

$13.43

$0.66 (5.17%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

All Avidity Biosciences Articles

2 Articles

Trey Thoelcke | Feb 5, 2025 at 8:45 AM EST

Prediction: This Pharma Stock Will Be the Best Performer in 2025

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Rich Duprey | Sep 8, 2024 at 7:43 AM EDT

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled…